Intensity Therapeutics initiated with a Buy at Alliance Global Partners

Alliance Global Partners initiated coverage of Intensity Therapeutics (INTS) with a Buy rating and $8.50 price target Intensity is developing INT230-6, a Phase 3 asset that both decreases the tumor burden while also activating an increased immune system response to better recognize and target the cancer, for advanced soft tissue sarcoma and triple negative breast cancer. The firm values INT230-6 for STS at $6 per share, INT230-6 for TNBC at $2 per share, and the remaining compounds and cash at 50c per share, the analyst noted.